IV lidocaine for pain control in lumbar fusion
Effect of Intraoperative Intravenous Lidocaine Infusion on Postoperative Opioid Consumption and Recovery After Lumbar Fusion Surgery: A Randomized Controlled Trial
This project will test whether giving an intravenous lidocaine infusion during elective lumbar fusion reduces opioid use and speeds early recovery in adults aged 18–65.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 110 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Ankara City Hospital Bilkent Academic / other |
| Locations | 1 site (Ankara) |
| Trial ID | NCT07488832 on ClinicalTrials.gov |
What this trial studies
This is a prospective, randomized, placebo-controlled trial enrolling adults (18–65 years, ASA I–II) scheduled for elective lumbar fusion. Participants are randomly assigned to receive an IV lidocaine bolus followed by continuous infusion during surgery or an equivalent-volume saline placebo. The primary outcome is cumulative postoperative opioid consumption in the first 24 hours; secondary outcomes include intraoperative opioid use, postoperative pain scores, and early recovery measures. The intervention is given only during the surgical period and standard perioperative care otherwise continues.
Who should consider this trial
Good fit: Ideal candidates are adults 18–65 years old with ASA physical status I–II who are scheduled for elective lumbar fusion and can give informed consent and cooperate with postoperative assessments.
Not a fit: Patients with ASA ≥III, BMI >35, chronic opioid use, pregnancy, severe cardiac/hepatic/renal disease, or known lidocaine allergy are excluded and unlikely to benefit from this protocol.
Why it matters
Potential benefit: If successful, the intervention could reduce postoperative opioid requirements, lower opioid-related side effects, and promote faster early recovery after lumbar fusion.
How similar studies have performed: Previous perioperative studies in other surgical populations have shown that systemic lidocaine can reduce pain and opioid use, but evidence specifically for lumbar fusion is limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age between 18 and 65 years * Scheduled for elective lumbar fusion surgery under general anesthesia * American Society of Anesthesiologists (ASA) physical status I-II * Ability to provide written informed consent Exclusion Criteria: * Refusal to participate in the study * ASA physical status ≥III * Body mass index \>35 kg/m² * Known allergy or hypersensitivity to lidocaine or study medications * Severe cardiac, hepatic, or renal disease * Pregnancy * Neurological disorders affecting pain assessment * Chronic opioid use * Use of opioids or antiemetic drugs before surgery * Inability to cooperate with postoperative assessments
Where this trial is running
Ankara
- Ankara Bilkent City Hospital — Ankara, Turkey (Türkiye) (Recruiting)
Study contacts
- Principal investigator: Gokhan Erdem, MD, PhD — Department of Anesthesiology and Reanimation, Ankara Bilkent City Hospital, Ankara, Turkey
- Study coordinator: Ankara Bilkent City Hospital
- Email: ankarasehir@saglik.gov.tr
- Phone: +90 312 552 6000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.